183 related articles for article (PubMed ID: 16225927)
1. Side-effect profile of brimonidine tartrate in children.
Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP
Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
thoe Schwartzenberg GW; Buys YM
Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
[TBL] [Abstract][Full Text] [Related]
3. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
4. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Bowman RJ; Cope J; Nischal KK
Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
[TBL] [Abstract][Full Text] [Related]
5. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
6. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
7. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
8. Exposure to topical apraclonidine in children with glaucoma.
Wright TM; Freedman SF
J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
10. Is brimonidine ophthalmic a safe therapy for infants?
Daubert GP
J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Katz LJ; Simmons ST; Craven ER
Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of brimonidine in children with glaucoma.
Enyedi LB; Freedman SF
J AAPOS; 2001 Oct; 5(5):281-4. PubMed ID: 11641636
[TBL] [Abstract][Full Text] [Related]
13. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of brimonidine 0.2 per cent as adjunctive therapy to beta-blockers: a comparative study between POAG and CACG in Asian eyes.
Ruangvaravate N; Kitnarong N; Metheetrairut A; Danwiriyakul W
J Med Assoc Thai; 2002 Aug; 85(8):894-900. PubMed ID: 12403210
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
Detry-Morel M; Dutrieux C
J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
[TBL] [Abstract][Full Text] [Related]
17. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
18. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
Titouamane S; Baudouin C
J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
[TBL] [Abstract][Full Text] [Related]
19. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
Yuen NS; Cheung P; Hui SP
Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
[TBL] [Abstract][Full Text] [Related]
20. [The effect of brimonidine on postoperative hypertonia after an extracapsular cataract extraction].
Katsimpris JM; Petropoulos IK; Voros G; Gerodimos G; Pharmakakis NM
J Fr Ophtalmol; 2003 Apr; 26(4):369-74. PubMed ID: 12843894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]